文献速递创伤与烧伤复苏、休克与脓毒症

创伤大量输血中冷沉淀的最优剂量

Optimal dose of cryoprecipitate in massive transfusion following trauma.
PubMed 文献 · J Trauma Acute Care Surg · 2023-06-19
一句话结论创伤大量输血时,每7~8U红细胞给予1个混合单位(100mL)冷沉淀可能为最优剂量,可获得生存获益并避免不必要输血。

研究基于美国外科医师学会创伤质量改进项目(2013—2019年)12,916例接受大量输血(4小时内≥4U红细胞、≥1U新鲜冰冻血浆、≥1U血小板)的成人创伤患者,分析4小时内红细胞与冷沉淀比值(RBC:Cryo)与24小时死亡率的关系。在5,511例(42.7%)接受冷沉淀的患者中,4小时内红细胞与冷沉淀中位输注量分别为11U(四分位距7~19U)和2U(四分位距1~3U)。与未使用冷沉淀相比,仅RBC:Cryo≤8:1与显著生存获益相关,而RBC:Cryo>8:1的较低冷沉淀剂量与24小时死亡率降低无关;与最大冷沉淀剂量(RBC:Cryo 1:1~2:1)相比,RBC:Cryo至7:1~8:1时24小时死亡率无差异,而RBC:Cryo>8:1的较低剂量与24小时死亡率显著升高相关。作者认为每7~8U红细胞给予1个混合单位(100mL)冷沉淀可能是创伤复苏中的最优剂量。

要点

  • 在12,916例大量输血创伤患者中,与未使用冷沉淀相比,仅RBC:Cryo≤8:1与显著生存获益相关。
  • 与最大冷沉淀剂量(RBC:Cryo 1:1~2:1)相比,RBC:Cryo 7:1~8:1时24小时死亡率无差异。
  • RBC:Cryo>8:1(冷沉淀剂量较低)与24小时死亡率显著升高相关。
  • 接受冷沉淀的5,511例(42.7%)患者4小时内红细胞与冷沉淀中位输注量分别为11U(四分位距7~19U)和2U(四分位距1~3U)。
  • 作者认为每7~8U红细胞给予1个混合单位(100mL)冷沉淀可能是创伤复苏的最优剂量。

适用人群与场景

  • 美国外科医师学会创伤质量改进项目(2013—2019年)中接受大量输血的成人创伤患者,大量输血定义为4小时内≥4U红细胞、≥1U新鲜冰冻血浆和≥1U血小板。

诊断标准与关键阈值

  • 大量输血定义:4小时内≥4U红细胞、≥1U新鲜冰冻血浆和≥1U血小板。
  • 1U冷沉淀定义为100mL的混合单位。
  • RBC:Cryo比值按就诊后4小时内输注的血制品计算。

研究设计与关键结果

  • 研究纳入12,916例患者,其中5,511例(42.7%)接受冷沉淀;接受冷沉淀者4小时内红细胞和冷沉淀中位输注量分别为11U(四分位距7~19U)和2U(四分位距1~3U)。
  • 与未使用冷沉淀相比,仅RBC:Cryo≤8:1与显著生存获益相关,而RBC:Cryo>8:1的较低冷沉淀剂量与24小时死亡率降低无关。
  • 与最大冷沉淀剂量(RBC:Cryo 1:1~2:1)相比,RBC:Cryo 7:1~8:1时24小时死亡率无差异,而RBC:Cryo>8:1与24小时死亡率显著升高相关。
  • 多因素logistic回归校正了红细胞、血浆和血小板输注量、整体与区域损伤严重程度及其他相关变量。

证据类型、等级与局限

  • 证据类型:预后与流行病学研究;证据等级:Level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为每7~8U红细胞给予1个混合单位(100mL)冷沉淀可能是创伤复苏中的最优剂量,可获得显著生存获益并避免不必要血制品输注。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: While cryoprecipitate (Cryo) is commonly included in massive transfusion protocols for hemorrhagic shock, the optimal dose of Cryo transfusion remains unknown. We evaluated the optimal red blood cell (RBC) to RBC to Cryo ratio during resuscitation in massively transfused trauma patients.

METHODS: Adult patients in the American College of Surgeon Trauma Quality Improvement Program (2013-2019) receiving massive transfusion (≥4 U of RBCs, ≥1 U of fresh frozen plasma, and ≥1 U of platelets within 4 hours) were included. A unit of Cryo was defined as a pooled unit of 100 mL. The RBC:Cryo ratio was calculated for blood products transfused within 4 hours of presentation. The association between RBC:Cryo and 24-hour mortality was analyzed with multivariable logistic regression adjusting for the volume of RBC, plasma and platelet transfusions, global and regional injury severity, and other relevant variables.

RESULTS: The study cohort included 12,916 patients. Among those who received Cryo (n = 5,511 [42.7%]), the median RBC and Cryo transfusion volume within 4 hours was 11 U (interquartile range, 7-19 U) and 2 U (interquartile range, 1-3 U), respectively. Compared with no Cryo administration, only RBC:Cryo ratios ≤8:1 were associated with a significant survival benefit, while lower doses of Cryo (RBC:Cryo >8:1) were not associated with decreased 24-hour mortality. Compared with the maximum dose of Cryo administration (RBC:Cryo, 1:1-2:1), there was no difference in 24-hour mortality up to RBC:Cryo of 7:1 to 8:1, whereas lower doses of Cryo (RBC:Cryo, >8:1) were associated with significantly increased 24-hour mortality.

CONCLUSION: One pooled unit of Cryo (100 mL) per 7 to 8 U of RBCs could be the optimal dose of Cryo in trauma resuscitation that provides a significant survival benefit while avoiding unnecessary blood product transfusions.

LEVEL OF EVIDENCE: Prognostic and Epidemiologic; Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Dorken-Gallastegi A, Bokenkamp M, Argandykov D, et al. Optimal dose of cryoprecipitate in massive transfusion following trauma. J Trauma Acute Care Surg. 2023. PMID: 37335138. doi:10.1097/TA.0000000000004060

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。